Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 48,204 shares, a decrease of 59.8% from the August 31st total of 119,854 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 259,918 shares, the short-interest ratio is presently 0.2 days.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ENLV shares. Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Tuesday, September 22nd. Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Finally, Zacks Research upgraded shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $247.50.

Hedge Funds Weigh In On Enlivex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. WINTON GROUP Ltd purchased a new stake in Enlivex Therapeutics during the second quarter valued at approximately $55,000. Bank of America Corp DE increased its stake in shares of Enlivex Therapeutics by 53.2% in the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after purchasing an additional 45,303 shares in the last quarter. Finally, Susquehanna International Group LLP increased its stake in shares of Enlivex Therapeutics by 1,428.5% in the 2nd quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock worth $87,000 after purchasing an additional 147,334 shares in the last quarter. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Trading Down 11.3%

ENLV stock traded down $0.07 during trading on Monday, reaching $0.53. The stock had a trading volume of 461,635 shares, compared to its average volume of 133,405. The firm has a market cap of $9.27 million, a PE ratio of -0.06 and a beta of 1.42. The stock’s 50 day moving average is $1.77 and its two-hundred day moving average is $8.17. Enlivex Therapeutics has a 52 week low of $0.52 and a 52 week high of $27.15.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore immune-system balance, or immune homeostasis, in patients experiencing severe or dysregulated inflammation. The company focuses on conditions in which an excessive or impaired immune response may contribute to organ damage and other serious complications.

Its lead product candidate, Allocetra-OTS, is an off-the-shelf cell therapy made from healthy apoptotic cells.